Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 10/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | PHGDH | O43175 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615357 | 0.85 | AVPR1A (0.76) | AVPR1AMAPTL3MBTL1GAAMAPK1 | |
| SCHEMBL615561 | 0.78 | AVPR1A (0.67) | AVPR1AMAPTL3MBTL1NPSR1LMNA | |
| SCHEMBL614990 | 0.76 | AVPR1A (0.70) | AVPR1AALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL28322333 | 0.76 | MAPT (0.69) | MAPTL3MBTL1GAAMAPK1NPSR1 | |
| SCHEMBL8985868 | 0.76 | GFER (0.56) | AVPR1AMAPTL3MBTL1NPSR1LMNA | |
| SCHEMBL612438 | 0.75 | AVPR1A (1.00) | AVPR1AMAPTGAAHTT | |
| SCHEMBL15911569 | 0.75 | MAPT (0.67) | MAPTL3MBTL1GAAMAPK1NPSR1 | |
| SCHEMBL613531 | 0.75 | AVPR1A (0.82) | AVPR1AMAPK1NPSR1ALDH1A1KMT2A | |
| SCHEMBL614602 | 0.72 | AVPR1A (0.70) | AVPR1A | |
| SCHEMBL615324 | 0.72 | AVPR1A (0.67) | AVPR1AMAPTMAPK1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | claimed |
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA | 2010-09-02 | — | — | US | claimed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | claimed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| CN-102295636-A | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA | 2010-09-02 | — | — | US | disclosed |
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA | 2010-09-02 | — | — | US | disclosed |
| US-7781436-B2 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781436-B2 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101277945-A | Indol-3-yl-carbonyl-piperidine and piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-01 | — | — | CN | disclosed |
| EP-1917255-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885MAPT 4078/4885L3MBTL1 4343/4885 |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885MAPT 4078/4885L3MBTL1 4343/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885MAPT 4078/4885L3MBTL1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.